



MMV-supported projects



Target product profiles (TPPs)

- 3-day cure, artemisinin-based combination therapies (TPP1)
- Uncomplicated malaria treatments and resistance management (TPP1)
- Intermittent preventive treatment (TPP1)
- Severe malaria treatment/pre-referral intervention (TPP1)
- Products targeting prevention of relapse for *P. vivax* (TPP1)
- Prophylaxis (TPP2)

Brand names: 1. Coartem® *Dispersible*; 2. Artesun®; 3. Larinate® 60mg; 4. Eurartesim®; 5. Pyramax® tablets or granules; 6. ASAQ Winthrop®; 7. SPAQ-CO™; 8. Supyra®; 9. 100 mg Artesunate Rectocaps; 10. Artecip™; 11. *Krintafel/Kozenis* (Trademarks owned or licensed by GSK)

Target candidate profiles (TCPs)

- ⊗ Asexual blood stages (TCP 1)
 - ⊗ Relapse prevention (TCP 3)
 - ⊗ Causal prophylaxis (TCP 4)
 - ⊗ Transmission reduction (TCP 5, 6)
-
- ⊗ Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ.
 - ⊗ Global Fund Expert Review Panel reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing
 - ⊗ Paediatric formulation
 - ⊗ WHO prequalified OR approved/positive opinion by regulatory bodies who are ICH* members/observers
 - ⊗ Via a bioequivalence study
 - (-) Past partners are in brackets

* International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use